USA
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Moffitt Cancer Center.
TAMPA, Fla., and NASHVILLE, Tenn. — Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE’s state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport’s CRYOGENE business unit is a leading biorepository for the life sciences industry that is focused on the secure storage of biological specimens and associated services.
“Our goal is to make Speros the cell and gene therapy capital of the world,” said Patrick Hwu, M.D., president and CEO of Moffitt. “With the addition of CRYOGENE, we will accelerate discovery by igniting collaborations and partnerships across disciplines to bring new therapies to patients faster and save more lives. This collaboration builds upon Moffitt’s longstanding partnership with Cryoport’s CRYOGENE and serves as an initial step in transforming our campus into a global epicenter of innovation.”
This is the News section of the company profile page for Moffitt Cancer Center on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.